黑料官网

header-logo
GettyImages-609179959-hero
Hematology and Oncology
Kathryn Flynn, PhD, MS

Kathryn Flynn, PhD

Professor, Vice Chair for Research

Locations

  • Department of Medicine
    Division of Hematology and Oncology

Biography

Dr. Kathryn Flynn is a professor of medicine at the 黑料官网, Division of Hematology and Oncology. She is also the Senior Scientific Director for Patient-Reported Outcomes in the Center for International Blood and Marrow Transplant Research (CIBMTR). She was trained in sociology (BA, MS) and population health sciences (PhD).

Leadership Positions

  • Senior Scientific Director for Patient-Reported Outcomes Center for International Blood and Marrow Transplant Research
  • Vice Chair for Research, Department of Medicine

Research Interests

Dr. Flynn’s research focuses on the measure development and analysis of patient-reported outcomes as well as mixed methods approaches to understanding and improving patient-provider communication and patient decision making. She was a co-investigator in the PROMIS Network – NIH Roadmap initiative to standardize patient-reported outcomes measurement across diseases. She co-led development of the PROMIS Sexual Function and Satisfaction measure. She currently co-leads an NICHD R21 as well as a 14-site NCI-funded R01 examining clinical and patient-reported outcomes among patients with chronic myeloid leukemia who discontinue targeted therapies.

Publications

  • (Bretschneider CE, Smerdon C, Bieber B, Goodrich N, Griffith J, Lai HH, Hokanson JA, Kirby AC, Smith A, Guerrero M, Gutta S, Flynn KE, John K, Bradley CS, LURN Study Group.) J Sex Med. 2025 Jun 03;22(6):1035-1042 PMID: 40269441 SCOPUS ID: 2-s2.0-105008306977 04/24/2025

  • (Dickstein DR, Kapouranis T, Sigel K, Wheldon CW, Nvepu E, Javier NM, Stewart R, Galsky M, Sfakianos J, Safer JD, Stock R, Goodman K, Rosser BRS, Flynn KE, Marshall DC.) Int J Radiat Oncol Biol Phys. 2025 Jun 01;122(2):416-423 PMID: 40057858 SCOPUS ID: 2-s2.0-86000369649 03/09/2025

  • (Sunji N, Tovar N, Flynn KE, Hauspurg A, Palatnik A.) Hypertension. 2025 May;82(5):e102-e104 PMID: 40238906 PMCID: PMC12007699 SCOPUS ID: 2-s2.0-105003279786 04/16/2025

  • (Flynn KE, Clements J, DeMairo K, Hiller J, Wei D, Hazra NC, Constantinescu C, Meng Y, Latremouille-Viau D, Jadhav K, Marquez G, Yang D, Damon A, Sadek I, Guérin A, Schoenbeck K.) J Natl Compr Canc Netw. 2025 Mar 28;23(3.5) PMID: 40154303 SCOPUS ID: 2-s2.0-105002492474 03/29/2025

  • (Flynn KE, Clements J, DeMairo K, Hiller J, Wei D, Hazra NC, Constantinescu C, Meng Y, Latremouille-Viau D, Jadhav K, Marquez G, Yang D, Damon A, Sadek I, Guérin A, Schoenbeck K.) J Natl Compr Canc Netw. 2025 Mar 28;23(3.5) PMID: 40154325 SCOPUS ID: 2-s2.0-105002491276 03/29/2025

  • (Sarker J, Atallah EL, Flynn KE, Winn AN.) Leuk Lymphoma. 2025 Mar 25:1-6 PMID: 40131232 03/25/2025

  • (Basir MA, McDonnell SM, Brazauskas R, Kim UO, Ahamed SI, McIntosh JJ, Pizur-Barnekow K, Pitt MB, Kruper A, Leuthner SR, Flynn KE.) Patient Educ Couns. 2025 Mar;132:108599 PMID: 39647248 PMCID: PMC11757045 SCOPUS ID: 2-s2.0-85211172216 12/09/2024

  • (Burek AG, Porada K, Plunk MR, Corey Bauer S, Liegl M, Pan A, Flynn KE, Brousseau DC, Gedeit R, Ullman AJ.) Hosp Pediatr. 2025 Feb 01;15(2):124-134 PMID: 39848287 SCOPUS ID: 2-s2.0-85216871598 01/24/2025

  • (Neuner JM, Stolley M, Kamaraju S, Tiegs J, Sparapani R, Makris V, Flynn KE.) Breast Cancer Res Treat. 2025 Feb;209(3):541-552 PMID: 39592520 SCOPUS ID: 2-s2.0-85210370572 11/27/2024

  • (Sarker J, Atallah EL, Flynn KE, Winn AN.) Leukemia and Lymphoma. 2025 SCOPUS ID: 2-s2.0-105001963122 01/01/2025

  • (McDonnell SM, Flynn KE, Barnekow K, Kim UO, Brazauskas R, Ahamed SI, McIntosh JJ, Pitt MB, Leuthner SR, Kruper A, Basir MA.) PEC Innov. 2024 Dec 15;5:100346 PMID: 39434846 PMCID: PMC11491957 10/22/2024

  • (McDonnell SM, Flynn KE, Barnekow K, Kim UO, Brazauskas R, Ahamed SI, McIntosh JJ, Pitt MB, Leuthner SR, Kruper A, Basir MA.) Pec Innovation. 15 December 2024;5 SCOPUS ID: 2-s2.0-85205455964 12/15/2024

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.